Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis
- 1 February 2018
- journal article
- research article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 16 (2) , 260-267.e1
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitisGut, 2011
- Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune HepatitisGastroenterology, 2010
- Application of the 2010 American Association for the Study of Liver Diseases Criteria of Remission to a Cohort of Italian Patients With Autoimmune HepatitisHepatology, 2010
- Diagnosis and Management of Autoimmune HepatitisHepatology, 2010
- Budesonide in previously untreated autoimmune hepatitisLiver International, 2005
- Pharmacokinetics and Pharmacodynamic Action of Budesonide in Early– and Late–Stage Primary Biliary CirrhosisHepatology, 2003
- Treatment of Autoimmune HepatitisSeminars in Liver Disease, 2002
- Oral budesonide for treatment of autoimmune chronic active hepatitisAlimentary Pharmacology & Therapeutics, 1994
- Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.Gut, 1975
- CONTROLLED TRIAL OF PREDNISONE AND AZATHIOPRINE IN ACTIVE CHRONIC HEPATITISThe Lancet, 1973